MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

Background:Malignant pleural mesothelioma (MPM) is a highly aggressive tumour that is first-line treated with a combination of cisplatin and pemetrexed. Until now, predictive and prognostic biomarkers are lacking, making it a non-tailored therapy regimen with unknown outcome. P53 is frequently inactivated in MPM, but mutations are extremely rare. MDM2 and P14/ARF are upstream regulators of P53 that may contribute to P53 inactivation.Methods:A total of 72 MPM patients were investigated. MDM2 immunoexpression was assessed in 65 patients. MDM2 and P14/ARF mRNA expression was analysed in 48 patients of the overall collective. The expression results were correlated to overall survival (OS) and progression-free survival (PFS).Results:OS and PFS correlated highly significantly with MDM2 mRNA and protein expression, showing a dismal prognosis for patients with elevated MDM2 expression (for OS: Score (logrank) test: P⩽0.002, and for PFS: Score (logrank) test; P<0.007). MDM2 was identified as robust prognostic and predictive biomarker for MPM on the mRNA and protein level. P14/ARF mRNA expression reached no statistical significance, but Kaplan–Meier curves distinguished patients with low P14/ARF expression and hence shorter survival from patients with higher expression and prolonged survival.Conclusions:MDM2 is a prognostic and predictive marker for a platin–pemetrexed therapy of patients with MPMs. Downregulation of P14/ARF expression seems to contribute to MDM2-overexpression-mediated P53 inactivation in MPM patients.

[1]  H. Kindler,et al.  Malignant pleural mesothelioma: an update on biomarkers and treatment. , 2009, Chest.

[2]  R. Gjerset,et al.  Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability. , 2003, Cancer research.

[3]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[4]  F. Westermann,et al.  Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3 , 2011, Molecular Cancer Therapeutics.

[5]  H. Popper,et al.  Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  L. Wen,et al.  ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation , 2010, Oncogene.

[7]  N. Perkins,et al.  Regulation of NF‐κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor , 2005, The EMBO journal.

[8]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[9]  T. Treasure,et al.  Pleural mesothelioma: little evidence, still time to do trials , 2004, The Lancet.

[10]  Robert M. White,et al.  Pemetrexed in malignant pleural mesothelioma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  R. Stahel,et al.  p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. , 2006, Neoplasia.

[12]  P. Secchiero,et al.  Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts , 2013, Clinical Cancer Research.

[13]  K. Schmid,et al.  FFPE tissue as a feasible source for gene expression analysis--a comparison of three reference genes and one tumor marker. , 2013, Pathology, research and practice.

[14]  J. Testa,et al.  Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis , 2011, PloS one.

[15]  C. Manegold,et al.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments. , 2004, Lung cancer.

[16]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[17]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[18]  K. Krejcy,et al.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments , 2003, British Journal of Cancer.

[19]  Nishant Bhatta,et al.  MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro , 2011, Journal of gastroenterology and hepatology.

[20]  A. Churg,et al.  Changing trends in US mesothelioma incidence , 2004, Occupational and Environmental Medicine.

[21]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[22]  Cindy B. Yeoh,et al.  Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Y. Matsuno,et al.  Morphology of 9p21 homozygous deletion‐positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology , 2013, Cancer cytopathology.

[24]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[25]  D. Spandidos,et al.  Deregulation of the tumour suppressor genes p14ARF, p15INK4b, p16INK4a and p53 in basal cell carcinoma , 2009, The British journal of dermatology.

[26]  F. Hirsch,et al.  Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  B. Kaina,et al.  Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair , 2014, Oncogene.

[28]  K. Schmid,et al.  Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. , 2014, Future oncology.

[29]  K. Schmid,et al.  ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. , 2013, Clinical lung cancer.

[30]  D. Weiss,et al.  Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. , 2001, International journal of oncology.

[31]  Ranjit K. Goudar.  Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma , 2008, Therapeutics and clinical risk management.

[32]  A. Thompson,et al.  p53-Based cyclotherapy: exploiting the ‘guardian of the genome' to protect normal cells from cytotoxic therapy , 2013, British Journal of Cancer.

[33]  U. Kees,et al.  MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63 , 2011, Oncogene.

[34]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[35]  S. Toyooka,et al.  Advances in the molecular biology of malignant mesothelioma. , 2008, Acta medica Okayama.

[36]  Jun Qin,et al.  ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor , 2005, Cell.

[37]  T. Shinohara,et al.  [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[38]  C. Manegold.  Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  G. Scagliotti,et al.  Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Chirieac,et al.  p16 Deletion in sarcomatoid tumors of the lung and pleura. , 2013, Archives of pathology & laboratory medicine.

[41]  H. Kindler.  Systemic Treatments for Mesothelioma: Standard and Novel , 2008, Current treatment options in oncology.

[42]  A. Nicholson,et al.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial , 2008, The Lancet.

[43]  G. Wahl,et al.  Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.

[44]  Gong Yang,et al.  Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. , 2014, Biochimica et biophysica acta.

[45]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[46]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[47]  T. Papp,et al.  Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. , 2001, Oncology reports.

[48]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  H. Leonhardt,et al.  Visualization and targeted disruption of protein interactions in living cells , 2013, Nature Communications.

[50]  F. Galateau-Sallé,et al.  Malignant Pleural Mesothelioma: From the Bench to the Bedside , 2012, Respiration.

[51]  Jessica E. Bolden,et al.  Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. , 2009, Cancer letters.

[52]  S. Ramalingam,et al.  Recent Advances in the Treatment of Malignant Pleural Mesothelioma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[53]  A. Krasinskas,et al.  The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. , 2011, American journal of clinical pathology.

[54]  A. Bahnassy,et al.  Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. , 2012, Experimental and molecular pathology.

[55]  M. Feldman,et al.  Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[56]  A. Nicholson,et al.  CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma—A miRNA microarray analysis , 2009, Genes, chromosomes & cancer.

[57]  A. Krasinskas,et al.  CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival , 2010, Modern Pathology.

[58]  V. Rusch,et al.  Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  D. Landau,et al.  Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[60]  J. Zavadil,et al.  Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma* , 2010, The Journal of Biological Chemistry.

[61]  K. Kiura,et al.  Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma , 2012, Cancer science.

[62]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[63]  H. Popper,et al.  The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.